ImmunologybioRxivPreprint
Powerful synergistic effects of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors
N. K. Wolf, C. Blaj, L. Picton…·D. H. Raulet
The paper combines a STING agonist and an IL-2 superkine to enhance cancer immunotherapy, showing efficacy against both MHC I-deficient and MHC I+ tumors.
DOI 10.1101/2021.11.02.465022